BridgeMD
New treatment option for Lymphoma, Non-Hodgkin
Official title A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
ClinicalTrials.gov ID: NCT07308132
What this study is testing
What is JNJ-95566692?
JNJ-95566692 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for lymphoma, non-hodgkin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 with relapsed or refractory disease and no other...
- While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate...
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
- Participants of childbearing potential must have a negative highly sensitive (for example, beta [β]-human chorionic gonadotropin) pregnancy test at...
You likely can't join if
- Known active central nervous system involvement (CNS) or leptomeningeal involvement
- Prior solid-organ transplantation
- Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and...
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3...
- Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\<=) 1 (except alopecia, vitiligo...
The study team makes the final eligibility decision.
Where it's taking place
- Clayton, Australia
- Melbourne, Australia
- North Ryde, Australia
- Randwick, Australia
- Edegem, Belgium
- Liège, Belgium
- Lille, France
- Paris, France
- Pierre-Bénite, France
- Toulouse, France
- Barcelona, Spain
- Madrid, Spain
- Ankara, Turkey (Türkiye)
- Antalya, Turkey (Türkiye)
- Istanbul, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Clayton, Australia; Melbourne, Australia; North Ryde, Australia; Randwick, Australia; Edegem, Belgium; Liège, Belgium and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.